Printer Friendly

Candida Bloodstream Infections Among Persons Who Inject Drugs--Denver Metropolitan Area, Colorado, 2017-2018.

Candidemia, a bloodstream infection caused by Candida species, is typically considered a health care-associated infection, with known risk factors including the presence of a central venous catheter, receipt of total parenteral nutrition or broad-spectrum antibiotics, recent abdominal surgery, admission to an intensive care unit, and prolonged hospitalization (1,2). Injection drug use (IDU) is not a common risk factor for candidemia; however, in the context of the ongoing opioid epidemic and corresponding IDU increases, IDU has been reported as an increasingly common condition associated with candidemia (3) and methicillin-resistant Staphylococcus aureus bacteremia (4). Little is known about the epidemiology of candidemia among persons who inject drugs. The Colorado Department of Public Health and Environment (CDPHE) conducts population-based surveillance for candidemia in the five-county Denver metropolitan area, encompassing 2.7 million persons, through CDC's Emerging Infections Program (EIP). As part of candidemia surveillance, CDPHE collected demographic, clinical, and IDU behavior information for persons with Candida-positive blood cultures during May 2017-August 2018. Among 203 candidemia cases reported, 23 (11%) occurred in 22 patients with a history of IDU in the year preceding their candidemia episode. Ten (43%) of the 23 cases were considered community-onset infections, and four (17%) cases were considered community-onset infections with recent health care exposures. Seven (32%) of the 22 patients had disseminated candidiasis with end-organ dysfunctions; four (18%) died during their hospitalization. In-hospital IDU was reported among six (27%) patients, revealing that IDU can be a risk factor in the hospital setting as well as in the community. In addition to community interventions, opportunities to intervene during health care encounters to decrease IDU and unsafe injection practices might prevent infections, including candidemia, among persons who inject drugs.

Candidemia surveillance in the five-county Denver metropolitan area began in May 2017. Because candidemia is a reportable condition in the Denver metropolitan area, all surveillance area laboratories report Candida-positive blood cultures to CDPHE. As part of EIP surveillance, a case is defined as a blood culture positive for Candida spp. in a surveillance area resident; a recurrent case is defined as a new Candida-positive blood culture >30 days after the initial positive blood culture in the same patient. Cases were classified by patient epidemiologic exposures. Community-onset infections were defined as Candida-positive blood culture collected <3 days after hospital admission with no previous health care exposures (i.e., overnight hospitalizations, surgeries, long-term care, or long term acute care admissions in the previous 90 days and no central lines in place in the 2 days prior to culture collection). Health care-associated, community-onset infections were defined as a Candida-positive blood culture collected <3 days after hospital admission with previous health care exposures in the 90 days before the culture collection date. Hospital-onset infections were defined as blood cultures collected >3 days into the patient's hospitalization. Medical record reviews were performed to gather demographic and clinical information, including history of IDU, for all patients using a standardized case report form.

During the first 6 months of the surveillance program, CDPHE observed that approximately one in 10 cases of candidemia occurred in patients who had a documented history of IDU, and the majority of their Candida-positive blood cultures were collected on the day of hospital admission or shortly thereafter. This finding was unexpected given that candidemia typically occurs in severely ill, hospitalized patients (1,2). CDPHE and CDC conducted an epidemiologic investigation to describe candidemia among persons who inject drugs and identify potential interventions for prevention. For each case occurring in a person with documented IDU, medical records were reviewed to collect information on health care exposures, evidence of disseminated infections, coinfections, and drug use and associated practices before the Candida-positive cultures.

Among 203 candidemia cases reported during May 2017August 2018, 23 (11%) were identified in 22 patients with IDU in the past year; one patient had recurrent candidemia. Among these 22 patients, the average age was 37 years (range = 21-59 years), and 14 (64%) were women (Table). Eighteen (82%) of the patients were white, and four (18%) were Hispanic or Latino. Eleven (50%) patients had experienced homelessness or lived in transitional housing before the candidemia episode. Among the 22 candidemia patients with IDU, 10 (45%) had hepatitis C infection, including one who also had chronic hepatitis B infection and one who also had human immunodeficiency virus (HIV) infection. Other comorbidities included chronic lung disease; neurologic conditions such as seizures, epilepsy, or neuropathy; diabetes; alcohol abuse; and smoking tobacco during the preceding year.

Three patients left the hospital against medical advice, possibly without completing treatment for candidemia. Three additional patients had left against medical advice from at least one other medical encounter in the 6 months before their candidemia episode. Four (18%) patients died in the hospital 1-17 days after the Candida-positive blood culture, although whether candidemia was the direct cause of death was unknown.

Among the 23 infections in these 22 patients, the most common Candida species identified were Candida glabrata, Candida albicans, and Candida parapsilosis (Table). Ten (43%) of the 23 cases were identified as community-onset infections. Four (17%) cases were identified within 1 day of the patient's hospital admission or during a previous emergency department (ED) visit or hospitalization, after which the patient returned for treatment; these patients also had other health care exposures and were classified as health care-associated, community-onset infections. Nine (39%) cases were classified as hospital-onset infections. Among the nine patients with hospital-onset candidemia, the median interval from hospital admission to collection of the Candida-positive blood culture was 17 days (range = 4-107 days). Among all 23 candidemia cases, the median length of the candidemia-associated hospitalization was 10 days (range = 1-139 days).

In the 6 months before developing candidemia, the 22 patients had a mean of three previous inpatient or ED visits (range = 0-10). Including the admission for candidemia, the most common reasons for admission or ED visit were conditions related to drug use (i.e., dependence or withdrawal); nonspecific pain; mental or behavioral disorders; and infections and associated complications, including bacteremia, osteomyelitis, and sepsis.

Fifteen (68%) of the 22 patients had a blood culture yielding another organism (most commonly Staphylococcus aureus) either during the candidemia hospitalization or in the 6 months preceding the candidemia episode. In 10 (45%) patients, at least one other organism was identified in the same blood culture set as the one that yielded Candida spp. These included Staphylococcus aureus, coagulase negative Staphylococcus, Stenotrophomonas maltophilia, Pseudomonas fluorescens, Serratia marcescens, Enterobacter asburiae, Comamonas acidovorans, Pantoea spp., viridans Streptococcus, and Mucorales spp. Seven (32%) patients had disseminated candidiasis with end-organ dysfunctions, including endophthalmitis (one), septic emboli (one), osteomyelitis (three), and abscesses of the pelvis, psoas muscle, and upper mediastinum (three).

Drugs documented in the medical record or identified in urine testing in the 6 months before the candidemia episode included opioids (18 patients; 82%), methamphetamines (16; 73%), cannabinoids (seven; 32%), cocaine (six; 27%), benzodiazepines (four; 18%), ecstasy (MDMA) (one), and barbiturates (one). Two patients (9%) experienced "cotton fever," an illness characterized by rapid fever onset immediately following the injection of drugs filtered through cotton (5), in the 6 months before the candidemia hospitalization; four patients (18%) were reported to have engaged in unsafe injection practices, including using old syringes, cotton, filters, and dirty needles.

Six (27%) patients were observed injecting or attempting to inject drugs, including illicit drugs and pain medications that were not prescribed to them, while hospitalized. In addition, illicit drugs and drug paraphernalia, including syringes, spoons, and lighters, were found in four of these six patients' rooms.


Surveillance for candidemia in the Denver metropolitan area during 2017-2018 found that approximately one in 10 patients with candidemia had recent IDU. Patients with candidemia who had a history of IDU had high prevalences of IDU-associated conditions, including hepatitis C infection, homelessness, and disseminated candidiasis with end-organ dysfunction, increasing candidemia-associated morbidity; four of these patients died during their candidemia hospitalization.

Fourteen of the 22 patients in this analysis presumably became infected with Candida outside the hospital setting, likely related to IDU. In addition, the positive polymicrobial blood cultures in nearly half of the patients indicate that unsafe injection practices likely are prevalent, putting persons who inject drugs at risk for candidemia and other infections with bacteria, HIV, hepatitis C virus, and hepatitis B virus. Nine patients became infected in the hospital setting, likely because they either continued to inject drugs while hospitalized (six were observed injecting or attempting to inject drugs) or they had more typical health care-associated risk factors for candidemia.

The findings in this report are subject to at least two limitations. First, a relatively small number of patients with candidemia and a history of IDU were identified in the Denver metropolitan area during the study period; therefore, results of this analysis might not be generalizable to other geographic areas. Second, because IDU behaviors were identified by reviewing patient medical records, some patients with a history of IDU might have been missed if IDU practices were not documented. Similarly, information such as type of drugs used, frequency of use, and unsafe injection practices might not have been documented in the medical record.

This surveillance program identified IDU as a previously underrecognized risk factor for candidemia in Colorado. Usual candidemia prevention efforts, including antibiotic stewardship, catheter care, and antifungal prophylaxis, primarily occur in the health care setting to mitigate health care-associated risk factors. Prevention of candidemia and other infections in persons who inject drugs requires both health care and community-based interventions such as education about and resources for reducing IDU, increasing safe injection practices (e.g., cleaning the injection site, using sterile water in drug preparation, and avoiding shared injection equipment *), and initiation of medication-assisted treatment programs for persons injecting opioids.

Patients in this analysis were found to have had frequent health care encounters, including ED visits and inpatient admissions, in the 6 months preceding their candidemia episode. These health care encounters provide opportunities for targeted prevention efforts in addition to community-based interventions. Given the current opioid epidemic, it is important to monitor trends in drug use and IDU-related infections and to implement prevention interventions.


What is already known about this topic?

Candidemia is typically considered a health care-associated infection, but injection drug use (IDU) has emerged as an increasingly common condition associated with candidemia.

What is added by this report?

Among 203 candidemia cases in the Denver metropolitan area during May 2017-September 2018, 23 (11%) occurred in 22 patients who had a recent history of IDU. Many had disseminated infections with end organ dysfunction, and onset occurred both inside and outside the hospital setting. Six of the patients were observed injecting or attempting to inject drugs while hospitalized.

What are the implications for public health practice?

Opportunities to intervene during health care encounters to decrease IDU and unsafe injection practices might prevent infections, including candidemia. Preventing candidemia among persons who inject drugs requires both community-based and health care-based interventions.

Corresponding author: Devra M. Barter,, 303-692-2706.


(1.) Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag 2014;10:95-105.

(2.) Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63. https://doi. org/10.1128/CMR.00029-06

(3.) Zhang A, Shrum S, Williams S, et al. The changing epidemiology of candidemia in the United States: injection drug use as an increasingly common risk factor for candidemia. Presented at IDWeek 2018, San Francisco, CA; October 3-7, 2018. webprogram/Paper70077.html

(4.) Jackson KA, Bohm MK, Brooks JT, et al. Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs--six sites, 2005-2016. MMWR Morb Mortal Wkly Rep 2018;67:625-8. https://

(5.) Wurcel AG, Merchant EA, Clark RP, Stone DR. Emerging and underrecognized complications of illicit drug use. Clin Infect Dis 2015;61:1840-9.


Devra M. Barter, MS [1]; Helen L. Johnston, MPH [1]; Sabrina R. Williams, MPH [2]; Sharon V. Tsay, MD [2]; Snigdha Vallabhaneni, MD [2]; Wendy M. Bamberg, MD [1]

[1] Colorado Department of Public Health and Environment; [2] Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC.

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
TABLE. Characteristics of 22 patients with candidemia and a history
of injection drug use--Denver metropolitan area, Colorado,
May 2017-August 2018

Characteristic                                  No. (%)

Mean age, yrs (range)                        37 (21-59)

Women                                        14 (64)
Men                                           8 (36)

White                                        18 (82)
Asian                                         1 (5)
American Indian/Alaska Native                 1 (5)
Unknown                                       2 (9)

Not Hispanic or Latino                       18 (82)
Hispanic or Latino                            4 (18)

Hepatitis C, chronic                          9 (41)
Hepatitis C, acute                            1 (5)
Hepatitis B, chronic                          1 (5)
Human immunodeficiency virus infection        1 (5)
Chronic lung disease *                        4 (18)
Neurologic condition ([dagger])               8 (36)
Diabetes                                      5 (23)
Alcohol abuse                                 4 (18)
Smoking tobacco                              18 (82)

Experiencing homelessness/Transitional       11 (50)
Died                                          4 (18)
Left against medical advice                   3 (14)
Survived                                     15 (68)

Candida species in incident blood
culture ([section])
Candida glabrata                              8 (35)
Candida albicans                              6 (26)
Candida parapsilosis                          3 (13)
Candida dubliniensis                          2 (9)
Candida lusitaniae                            1 (4)
Candida lypolitica                            1 (4)
Candida rugosa                                1 (4)
C. albicans and Candida famata                1 (4)

Epidemiologic class ([section])
Community-onset ([paragraph])                10 (43)
Health care-associated, community-onset **    4 (17)
Hospital-onset ([dagger][dagger])             9 (39)
Hospitalization for candidemia,              23 (10, 1-139)
(median days, range) ([section])
Risk factors before Candida-positive
blood culture ([section])
Admission to an intensive care                6 (26)
unit ([section][section])
Recent abdominal surgery                      0
Presence of a central venous                 11 (48)
catheter ([paragraph][paragraph])
Receipt of broad-spectrum                    20 (87)
antibiotics ([section][section])
Receipt of total parenteral nutrition         0

* Includes chronic pulmonary diseases such as chronic obstructive
pulmonary disease, emphysema, chronic bronchitis, bronchiectasis,
interstitial lung disease, and asthma.

([dagger]) Includes epilepsy/seizure/seizure disorder and neuropathy.

([section]) Among 23 candidemia cases, which included one recurrent

([paragraph]) Positive blood culture <3 days after hospital admission
without prior health care exposures in the previous 90 days.

** Positive blood culture collected <3 days after hospital admission
with prior health care exposure in the previous 90 days.

([dagger][dagger]) Positive blood culture [greater than or equal to] 3
days into hospital admission.

([section][section]) 14 days before the Candida-positive blood culture.

([paragraph][paragraph]) On the day of, or in the 2 calendar days
before the Candida-positive blood culture.
COPYRIGHT 2019 U.S. Government Printing Office
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Barter, Devra M.; Johnston, Helen L.; Williams, Sabrina R.; Tsay, Sharon V.; Vallabhaneni, Snigdha;
Publication:Morbidity and Mortality Weekly Report
Geographic Code:1U8CO
Date:Mar 29, 2019
Previous Article:Imported Toxin-Producing Cutaneous Diphtheria--Minnesota, Washington, and New Mexico, 2015-2018.
Next Article:Investigation of Colorado Tick Fever Virus Disease Cases--Oregon, 2018.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |